News
Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune receptor (UIR) platform.
News
Prescient (ASX: PTX) shares jump 6% on new US patent
In an exciting update, Prescient Therapeutics (ASX: PTX) has announced that it has been granted a key US Patent for its OmniCAR portfolio “SpyCatcher and SpyTag: Universal…
News
Prescient Therapeutics delivers new clinic-ready cell therapy technology
Prescient Therapeutics Ltd (ASX:PTX)’s Steven Yatomi-Clarke outlines the company’s oncology treatment vision in a new interview with Proactive. The healthcare stock adopts a portfolio approach when…
News
Prescient (ASX: PTX) rolls out new cell therapy platform, CellPryme-M
In an upbeat development, clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has rolled out a second cell therapy platform, “CellPryme-M”. It is a high-performance cell therapy manufacturing…
News
Prescient unveils its latest powerful platform to advance personalised targeted cancer treatments
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy sector, unveiling its latest platform to advance CAR-T therapy globally….
Article, News
Prescient unveils new platform after 18 months in stealth mode
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named CellPryme-M, developed in collaboration with the Peter MacCallum Cancer Centre.
Article, News
Prescient Therapeutics unveils high performance cell therapy technology CellPryme-M
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a high-performance platform known as CellPryme-M which is designed to enhance…
Article, News
Prescient Therapeutics (ASX:PTX) unveils new cell therapy platform
Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M. CellPryme-M is a platform technology that produces superior cells during the cell…
News
Prescient Therapeutics Are Developing Game-Changing Cancer Treatments
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor to discuss the company’s innovative cancer treatments with the Biotech…
News
Prescient (ASX: PTX) expands its PTX-200 trial in AML patients
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has taken another step towards advancing its study of diseases of unmet medical needs. PTX will…